Trial Profile

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TH 9619 (Primary)
Indications Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms ODIN
Sponsors One-carbon Therapeutics

29 May 2026 According to One-carbon Therapeutics AB media release, data from the trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29th to June 2nd in Chicago, Illinois.
25 Aug 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com